Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year
* Marks five consecutive years of inclusion, reflecting continued progress in ESG management and execution * Recognition highlights proactive alignment with evolving expectations from global stakeholders INCHEON, South Korea, May 5, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a l...
Samsung Biologics Reports First Quarter 2026 Financial Results
* Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW 581 billion * Performance driven by full utilization across Plants 1 through 4 and robust operational execution * Strengthened the foundations for future growth through U.S. expansion and strategic partnerships INCHEO...
Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland
* Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters * Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support * Plans further investments to add capabilities and strengthe...
Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards
* Reinforcing long-term commitment to embedding sustainability across operations and partnerships * Continuing to support clients in delivering high-quality, life-saving medicines to patients worldwide INCHEON, South Korea, March 26, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a ...
Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system
* Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards * Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals * Validated system provides reliable, consistent carbon footprint data for clients I...
CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access
OSLO, Norway and INCHEON, South Korea, Feb. 3, 2026 /PRNewswire/ -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufact...
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
* Ranked in the top one percent among more than 150,000 companies assessed globally * Recognized for strengthened sustainability management across all four assessment categories INCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract developm...
Samsung Biologics reports fourth quarter and fiscal year 2025 financial results
* Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion * Maintained momentum through consistent operational performance and robust client demand * Strengthened foundation for long-term growth through expanded manufacturing readiness and operational scale INC...
Samsung Biologics recognized as a global leader in water security
* Company receives the highest Water Security rating in two years into participation * Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 10, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing or...
Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO
* Spin-off finalized within five months following board resolution * Proposal approved in shareholders' meeting with 99.9% support * Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced the ...
Samsung Biologics reports third quarter 2025 financial results
* Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion * Recorded Q3'25 consolidated operating profit of KRW 728.8 billion * Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea, Oct. 28, 2025 /PRNewswire/ -- Samsung...
Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™
* ExellenS TM applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed * ExellenS TM combines the company's commitment to operational excellence with its core manufacturing competencies, guided by standardization, simplification, and scalab...
Samsung Biologics reports second quarter 2025 financial results
* Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion * Recorded Q2'25 consolidated operating profit of KRW 475.6 billion * Solid momentum sustained through capacity ramp-up and stable project execution INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940...
Samsung Biologics launches drug screening services, Samsung Organoids
* Samsung Organoids to provide data-driven analysis of candidate molecules * Samsung Biologics expands service scope to include preclinical research INCHEON,South Korea, June 15, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organizat...
Samsung Biologics reports first quarter 2025 financial results
* Recorded Q1'25 consolidated revenue of KRW 1.3 trillion * Recorded Q1'25 consolidated operating profit of KRW 486.7 billion * Company expected to maintain steady growth momentum in 2025 driven by enhanced operational efficiency and diverse service offerings INCHEON, South Korea, April 23, ...
Samsung Biologics recognized for leadership band in water security
- Company receives leadership status and A- rating for efficient water resources management - Recognition reflects Samsung Biologics' commitment to water security and implementing sustainable practices across operations INCHEON, South Korea, Feb. 12, 2025 /PRNewswire/ -- Samsung Biolo...
Samsung Biologics reports fourth quarter and fiscal year 2024 financial results
* Recorded Q4'24 consolidated revenue of KRW 1.26 trillion * Recorded FY'24 consolidated revenue of KRW 4.55 trillion * Poised for further growth with expanded capacity and new service offerings INCHEON,South Korea, Jan. 22, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a globa...
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference
- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients' needs INCHEON, South Korea, Jan. 15, 2025 /PRNewswire/ -- Samsung...
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
* Samsung Biologics to offer ADC services at new dedicated facility * Extended collaboration reflects successful partnership and expertise INCHEON,South Korea, Jan. 9, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO),...
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
* Samsung Biologics to offer ADC services at new dedicated facility * Extended collaboration reflects successful partnership and expertise INCHEON,South Korea, Jan. 8, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO),...
